# SPINRAZA Clinical Trial Data
Keywords: SPINRAZA, SMA, NURTURE study, Neurofilament light-chain, SMN2, pre-symptomatic infants, clinical trials, adverse events

> This page provides detailed insights into the clinical trial data for SPINRAZA, focusing on its efficacy, safety, and outcomes in treating 5q spinal muscular atrophy (SMA), particularly in pre-symptomatic infants.

## Details
- [Introduction](#): Overview of the intended audience and disclaimer for healthcare professionals in the UK and Ireland.
- [Study Overview](#): The NURTURE study is a Phase II, open-label trial evaluating SPINRAZA in pre-symptomatic infants genetically diagnosed with SMA.
- [Key Findings](#): Sustained reductions in neurofilament light-chain (NfL) levels observed over time in the NURTURE study.
- [2-Copy Subgroup Analysis](#): Post hoc analysis excluding participants with specific baseline characteristics, aligning with other SMA clinical trials.
- [Study Design](#): Details on the NURTURE study design, including patient demographics, endpoints, and follow-up data over eight years.
- [Safety Outcomes](#): Explore the safety outcomes of SPINRAZA in pre-symptomatic patients.
- [Adverse Event Reporting](#): Instructions for reporting adverse events in the UK and Ireland, including contact information and links.
- [References](#): Citations and sources for the clinical trial data and related studies.